CMS draft expands drug price talks to include Medicare Part B drugs and outlines steps for future renegotiations; public ...

The Trump administration is already gearing up for another round of Medicare drug price negotiations, while OpenAI launched a ...

Conflicting QSSD definitions from two federal agencies mean that CMS’ administrative authority on drug pricing and payment is ...

Medicare seeks public comments as the agency plans to list up to 15 additional drugs selected for the third round of pricing ...

When Congress adopted the Inflation Reduction Act (IRA) in 2022, creating the Medicare Drug Price Negotiation Program (MDPNP), the bill did ...

The U.S. Centers for Medicare and Medicaid Services (CMS) said on Monday that it would announce a list of 15 drugs eligible ...

The executive order directs Trump's administration to take actions against "discriminatory" policies in foreign countries ...

The third cycle of the drug price negotiations will involve drugs under Medicare Part B. New prices are set to take effect in ...

Delaying Medicare’s ability to negotiate prices on small-molecule drugs until 13 years after FDA approval will decrease the ...

CMS proposed several changes for the third round of Medicare drug price negotiations, including the potential inclusion of some drugs under Medicare Part B, in a draft guidance published May 12. The ...

CMS said on Monday that it would announce a list of 15 drugs eligible for a third round of Medicare price negotiations by early February next year. For the first time, the list would include drugs ...

A federal appellate court has handed down the first appellate-level decision addressing the merits of drug manufacturers’ ...